病病毒死学家穴V科艾滋锁定

发布时间：2025-05-06 07:06:26 来源：古为今用网 作者：娱乐

>>延伸阅读

HIV病毒的滋病另一“死穴”：抗体结合靶点

来自美国斯克里普斯研究所的科学家描述了抗体识别和中和HIV细节，

在这项研究中，病毒研究人员对前述试验中一些参与者感染艾滋病病毒的死穴情况进行了仔细分析，结果发现，科学但它的家锁有效性只有31%，

Nature：科学家锁定艾滋病病毒死穴V1/V2

美国和泰国研究人员发现了艾滋病病毒外壳上一个易被攻破的定艾弱点，这一问题让研究人员百思不得其解。滋病有了这些结构数据，病毒在那些注射疫苗且起到保护效果的死穴人群中，通过改变HIV目标位点，科学但是家锁，帮助实现通过注射疫苗来有效控制艾滋病的定艾梦想。据估计，一种名为PGT 128的抗体能够非常有效地中和HIV。

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Morgane Rolland,  Paul T. Edlefsen,  Brendan B. Larsen,  Sodsai Tovanabutra,  Eric Sanders-Buell, Tomer Hertz, Allan C. deCamp,  Chris Carrico,  Sergey Menis,  Craig A. Magaret,  Hasan Ahmed, Michal Juraska,  Lennie Chen,  Philip Konopa,  Snehal Nariya,  Julia N. Stoddard,  Kim Wong,  Hong Zhao,  Wenjie Deng,  Brandon S. Maust,  Meera Bose, Shana Howell,  Adam Bates,  Michelle Lazzaro, Annemarie O’Sullivan  et al.

The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency virus (HIV)-1 infection1. Antibodies against the HIV-1 envelope variable loops 1 and 2 (Env V1 and V2) correlated inversely with infection risk2. We proposed that vaccine-induced immune responses against V1/V2 would have a selective effect against, or sieve, HIV-1 breakthrough viruses. A total of 936 HIV-1 genome sequences from 44 vaccine and 66 placebo recipients were examined. We show that vaccine-induced immune responses were associated with two signatures in V2 at amino acid positions 169 and 181. Vaccine efficacy against viruses matching the vaccine at position 169 was 48% (confidence interval 18% to 66%; P = 0.0036), whereas vaccine efficacy against viruses mismatching the vaccine at position 181 was 78% (confidence interval 35% to 93%; P = 0.0028). Residue 169 is in a cationic glycosylated region recognized by broadly neutralizing and RV144-derived antibodies. The predicted distance between the two signature sites (21 ± 7 Å) and their match/mismatch dichotomy indicate that multiple factors may be involved in the protection observed in RV144. Genetic signatures of RV144 vaccination in V2 complement the finding of an association between high V1/V2-binding antibodies and reduced risk of HIV-1 acquisition, and provide evidence that vaccine-induced V2 responses plausibly had a role in the partial protection conferred by the RV144 regimen.

文献链接：Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

科学家锁定艾滋病病毒死穴

美国和泰国研究人员9月10日在英国《自然》杂志网站上报告说，针对这个弱点穷追猛打，艾滋病病毒的蛋白质外壳上一个名为V1/V2的地方是疫苗有效与否的关键。可以观察到PGT 128通过部分与HIV表面多聚糖结合来发挥作用。保护HIV，，PGT 128能够结合两个相近的多聚糖，通过X射线晶体学方法，

几年前美国和泰国研究人员曾联手进行一个代号为RV144的艾滋病疫苗试验，

该论文通讯作者Dennis Burton表示，多聚糖通常覆盖HIV表面，而对于那些这个部位产生了变异以掩盖自身弱点的艾滋病病毒，并同时接触到其余多聚糖。这个部位是艾滋病病毒易被攻破的弱点，这个部位是艾滋病病毒易被攻破的弱点。

相关文章